1. LDL Cholesterol

3. A Critical Question

4. Treatment → Adherence → Outcomes

5. LDL-C Reduction and Platelet Activity in At-Risk Patients With Dyslipidemia

6. Percent Change From Baseline to Week 24 in LDL-C Alirocumab vs Placebo

7. LDL-C Reduction and Improvement in Left Ventricular Function

8. Safety Concerns With Very Low Levels of LDL-C

9. Inclusion Criteria FOURIER and ODYSSEY Outcomes

10. PCSK9 Inhibitors in the Acute Care Setting

11. Summary and Conclusions

12. Acute Coronary Syndromes and LDL Cholesterol

14. Introduction/Overview

15. Some Mechanisms in the Etiology of ACS

16. Results ODYSSEY OUTCOMES Trial

17. Secondary Prevention in Patients at Very High ASCVD Risk: AHA/ACC Cholesterol Management Guidelines

18. GLAGOV Trial Results Change in Percent Atheroma Volume

19. Ezetimibe IMPROVE-IT Results

20. Adverse Events FOURIER Evolocumab vs Placebo

21. Some Problems With Statins Some Patients Don't Respond, Others Can't Tolerate

22. Lowering LDL-C as Much as Possible and as Rapidly as Possible

23. FOURIER Cumulative Incidence of CV Events

24. FOURIER (Evolocumab) Baseline Characteristics

25. ODYSSEY OUTCOMES Event Rates Alirocumab vs Placebo

26. Patients in FOURIER Achieved Very Low LDL-C Levels, Without Harm and With CV Benefit

27. Early Introduction of Lipid-Lowering Therapy Post-ACS

28. Summary and Conclusions

29. Abbreviations